Group 1 - Energias de Portugal (EDPFY) is currently outperforming its peers in the Utilities sector, with a year-to-date return of approximately 11.3% compared to the sector average of 4.6% [4] - The Zacks Rank for Energias de Portugal is 2 (Buy), indicating a favorable outlook based on earnings estimate revisions and improving earnings outlooks [3] - Over the past 90 days, the Zacks Consensus Estimate for EDPFY's full-year earnings has increased by 7.6%, reflecting positive analyst sentiment [4] Group 2 - Energias de Portugal belongs to the Utility - Electric Power industry, which includes 58 stocks and currently ranks 87 in the Zacks Industry Rank, with an average gain of 4.9% this year [6] - Another stock in the Utilities sector, ENGIE BRASL EGA (EGIEY), has also shown strong performance with a year-to-date increase of 9.1% and a Zacks Rank of 2 (Buy) [5] - Both Energias de Portugal and ENGIE BRASL EGA are expected to continue their solid performance, making them noteworthy for investors interested in Utilities stocks [7]

Company Overview - Contineum Therapeutics, Inc. (CTNM) is part of the Medical group, which consists of 928 companies and is currently ranked 10 in the Zacks Sector Rank [2] - CTNM has a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimates and revisions [3] Performance Metrics - Over the past three months, the Zacks Consensus Estimate for CTNM's full-year earnings has increased by 11.5%, reflecting improved analyst sentiment [4] - Year-to-date, CTNM has achieved a return of approximately 33.1%, significantly outperforming the average return of 3.5% for Medical companies [4] Industry Comparison - CTNM belongs to the Medical - Biomedical and Genetics industry, which includes 449 stocks and is currently ranked 90 in the Zacks Industry Rank [6] - The Medical - Biomedical and Genetics industry has seen an average gain of 19.4% this year, indicating that CTNM is performing well within its specific industry [6] Additional Comparisons - Another Medical stock, Quest Diagnostics (DGX), has returned 6.7% year-to-date and has a Zacks Rank of 2 (Buy) [5] - Quest Diagnostics is part of the Medical - Outpatient and Home Healthcare industry, which has a lower year-to-date return of 3.6% and is ranked 196 [7]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the next 30 days [2] Value Score - The Value Style Score focuses on identifying undervalued stocks using ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight attractive investment opportunities [3] Growth Score - The Growth Style Score assesses a company's financial strength and future outlook by analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth potential [4] Momentum Score - The Momentum Style Score evaluates stocks based on price trends and earnings outlook changes, utilizing one-week price changes and monthly earnings estimate changes to identify favorable buying opportunities [5] VGM Score - The VGM Score combines Value, Growth, and Momentum Scores, providing a comprehensive rating that helps investors find stocks with the best overall potential [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7][8] Stock Example: EPAM Systems, Inc. - EPAM Systems, Inc. is rated 2 (Buy) on the Zacks Rank and has a VGM Score of A, with a Value Style Score of B, supported by a forward P/E ratio of 14.59, making it attractive for value investors [11] - The earnings estimate for fiscal 2025 has been revised upwards to $11.41 per share, with an average earnings surprise of +4.4%, indicating strong performance potential [12]

Group 1 - Ferguson plc (FERG) is a notable stock within the Industrial Products group, which consists of 180 companies, currently ranked 6 in the Zacks Sector Rank [2][3] - Ferguson plc has a Zacks Rank of 2 (Buy), indicating a positive outlook, with the consensus estimate for its full-year earnings increasing by 1.9% over the past quarter [3] - Year-to-date, Ferguson plc has returned approximately 15.7%, outperforming the average return of 12.6% for the Industrial Products group [4] Group 2 - Ferguson plc is part of the Manufacturing - General Industrial industry, which includes 43 stocks and is currently ranked 73 in the Zacks Industry Rank, with this group gaining about 10.4% year-to-date [6] - Flowserve (FLS), another stock in the Industrial Products sector, has also shown strong performance with a year-to-date return of 15% and a Zacks Rank of 2 (Buy) [4][5] - Both Ferguson plc and Flowserve are expected to continue their solid performance, making them attractive options for investors interested in Industrial Products stocks [7]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores provide a framework for evaluating stocks based on value, growth, and momentum characteristics [2] Zacks Style Scores Overview - Stocks are rated from A to F based on their value, growth, and momentum, with A indicating the highest potential for outperformance [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Score emphasizes a company's financial health and future growth potential, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Score identifies trends in stock prices and earnings estimates, helping investors time their positions effectively [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [6] Zacks Rank Integration - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.83% since 1988 [7] - The model includes a large number of stocks, making it essential for investors to utilize Style Scores to narrow down their choices [8] Investment Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks but high Style Scores may still pose risks due to downward earnings forecasts [10] Company Spotlight: Prudential Financial Inc. (PRU) - Prudential Financial, founded in 1875, offers a range of financial products and services globally [11] - PRU holds a 3 (Hold) Zacks Rank and a VGM Score of B, with a Value Style Score of A, indicating attractive valuation metrics [12] - Recent earnings estimates for fiscal 2026 have been revised upward, with a consensus estimate of $14.92 per share and an average earnings surprise of +7.1% [12] - Given its solid rankings and scores, PRU is recommended for investors' consideration [13]

Core Viewpoint - C.H. Robinson Worldwide (CHRW) has shown strong stock performance, with a 19.1% increase over the past month and a 24.2% gain since the beginning of the year, outperforming the Zacks Transportation sector and the Zacks Transportation - Services industry [1][2]. Financial Performance - The company has consistently exceeded earnings expectations, reporting an EPS of $1.23 against a consensus estimate of $1.12 in its last earnings report [2]. - For the current fiscal year, C.H. Robinson is projected to achieve earnings of $5.9 per share on revenues of $16.86 billion, reflecting a 15.91% increase in EPS and a 3.89% increase in revenues [3]. - For the next fiscal year, expected earnings are $6.83 per share on revenues of $18.08 billion, indicating a year-over-year change of 15.66% in EPS and 7.23% in revenues [3]. Valuation Metrics - The stock currently trades at a valuation of 33.8 times the current fiscal year EPS estimates, which is above the peer industry average of 23 times [7]. - On a trailing cash flow basis, the stock trades at 32.7 times compared to the peer group's average of 9.2 times [7]. - The PEG ratio stands at 2.1, suggesting that the stock is not among the top tier from a value perspective [7]. Zacks Rank and Style Scores - C.H. Robinson holds a Zacks Rank of 2 (Buy), supported by rising earnings estimates [8]. - The stock has a Value Score of D, while its Growth and Momentum Scores are A and B, respectively, resulting in a combined VGM Score of B [6][8].

Core Viewpoint - 1st Source (SRCE) has shown strong stock performance, with an 8% increase over the past month and a new 52-week high of $69.57, outperforming the Zacks Finance sector and the Zacks Banks - Midwest industry [1] Financial Performance - The company has a consistent record of positive earnings surprises, having met or exceeded earnings consensus estimates in the last four quarters, with the latest EPS reported at $1.67 against a consensus of $1.62 [2] - For the current fiscal year, 1st Source is projected to achieve earnings of $6.69 per share on revenues of $461 million, reflecting a 4.37% increase in EPS and a 6.28% increase in revenues [3] - The next fiscal year forecasts earnings of $6.88 per share on revenues of $477.9 million, indicating year-over-year changes of 2.84% in EPS and 3.67% in revenues [3] Valuation Metrics - The stock currently trades at 10.3X current fiscal year EPS estimates, aligning with the peer industry average, and at 11.2X on a trailing cash flow basis, also matching the peer group's average [7] - 1st Source has a Value Score of B, a Growth Score of D, and a Momentum Score of A, resulting in a combined VGM Score of B [6] Zacks Rank - The stock holds a Zacks Rank of 2 (Buy), supported by a favorable earnings estimate revision trend, indicating potential for further gains [8]

Core Viewpoint - OMV AG has shown strong stock performance, with a 5.6% increase over the past month and a new 52-week high of $15.04, outperforming the broader Oils-Energy sector and the Oil and Gas - Integrated - International industry [1] Financial Performance - OMV has consistently exceeded earnings expectations, reporting an EPS of $1.97 against a consensus estimate of $0.38 in its last earnings report [2] - For the current fiscal year, OMV is projected to earn $1.65 per share on revenues of $32.98 billion, with a slight year-over-year earnings growth of 1.23%. For the next fiscal year, earnings are expected to decline to $1.64 per share on revenues of $29.9 billion, reflecting a year-over-year change of -9.34% [3] Valuation Metrics - OMV's stock trades at 9.1 times the current fiscal year EPS estimates, below the peer industry average of 12.4 times. On a trailing cash flow basis, it trades at 3.5 times compared to the peer group's average of 3.8 times, indicating strong value positioning [7] - The company holds a Value Score of A, with Growth and Momentum Scores of B and D respectively, resulting in a combined VGM Score of A, making it appealing for value investors [6][7] Zacks Rank - OMV currently has a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts. This aligns with the recommendation for investors to select stocks with Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, suggesting potential for OMV shares in the near future [8]

Core Viewpoint - CVS Health is set to report its fourth-quarter 2025 results on February 10, with expectations of continued revenue growth despite a projected decline in earnings per share [1][2]. Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for CVS's fourth-quarter revenues is $103.1 billion, indicating a 5.5% growth from the previous year [2]. - The earnings estimate for the fourth quarter is 99 cents per share, reflecting a 16.8% decrease compared to the same period last year [2]. - Earnings estimates have increased by 3.1% over the past 60 days, indicating positive sentiment leading up to the earnings announcement [3]. Group 2: Factors Influencing Performance - The Health Care Benefits segment is expected to face challenges due to elevated medical costs and pressures from the Medicaid business, which may impact revenue [4]. - Positive contributions to revenue may come from the government business, particularly due to the Inflation Reduction Act's effects on the Medicare Part D program [5]. - Aetna's integration of pharmacy prescriptions and medical procedures is anticipated to enhance operational efficiency and revenue in the Health Care Benefits segment [6]. Group 3: Segment Performance Insights - The Pharmacy & Consumer Wellness segment is likely to have driven revenue growth, supported by the Rite Aid acquisition and increased prescription volume [9]. - The Health Services segment is projected to see a 7.2% year-over-year revenue increase, despite some short-term headwinds affecting client contracts [12]. - The Pharmacy & Consumer Wellness segment is expected to grow by 9.8% in the fourth quarter, benefiting from a favorable pharmacy drug mix and higher prescription volumes [15]. Group 4: Strategic Developments - CVS has completed a review of its Oak Street clinic operations, leading to the closure of underperforming locations, which is expected to improve revenue [11]. - The company is also planning to reduce the number of new Oak Street clinics to focus on sustainable margins [11]. - CVS is actively offering updated COVID-19 vaccines across its locations, which is expected to positively impact revenues in the fourth quarter [14].

分组1 - T. Rowe Price reported quarterly earnings of $2.44 per share, missing the Zacks Consensus Estimate of $2.47 per share, but showing an increase from $2.12 per share a year ago, resulting in an earnings surprise of -1.22% [1] - The company posted revenues of $1.93 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.79%, compared to year-ago revenues of $1.82 billion [2] - T. Rowe shares have increased by approximately 0.3% since the beginning of the year, while the S&P 500 has gained 1.1% [3] 分组2 - The earnings outlook for T. Rowe is mixed, with the current consensus EPS estimate for the coming quarter at $2.45 on revenues of $1.89 billion, and for the current fiscal year at $10.29 on revenues of $7.74 billion [7] - The Zacks Industry Rank for Financial - Investment Management is currently in the bottom 38% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Another company in the same industry, Sound Point Meridian Capital, Inc., is expected to report quarterly earnings of $0.55 per share, reflecting a year-over-year change of -11.3% [9]